Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX): 52 pipeline candidates · 1 upcoming catalyst · ~225 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
224.9 months
D/E 0.09 · 3% dilution
Lead: Phase 2
52 candidates
1 upcoming, next in ~2140d
0 buys · 8 sells (180d)
A transparent, data-derived signal for Janux Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$865.7M
Cash
$51.8M
Quarterly Burn
$12.3M
Runway
224.9 mo
Revenue
$3.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (52 candidates)
| Drug | Phase |
|---|---|
| [²¹²Pb]Pb-ADVC001 | Phase 1 |
| Abiraterone acetate | — |
| Androgen Deprivation Therapy | Phase 1 |
| Androgen-deprivation Therapy | Phase 4 |
| Antiandrogen | Phase 2 |
| Antiandrogen Therapy | Phase 2 |
| Apalutamide | Phase 1 |
| ARX517 | Phase 1 |
| Bicalutamide | Phase 2 |
| Blood and saliva samples | N/A |
Showing 10 of 52 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
190
Total value held
$895.6M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 11,189,693 | $155.5M |
| janus henderson group plc | 8,392,818 | $116.6M |
| blackrock, inc. | 5,433,233 | $75.5M |
| vanguard capital management llc | 3,622,730 | $50.4M |
| prosight management, lp | 3,550,000 | $49.3M |
| fmr llc | 2,535,724 | $35.2M |
| state street corp | 2,464,017 | $34.2M |
| alyeska investment group, l.p. | 1,601,089 | $22.3M |
| wellington management group llp | 1,597,650 | $22.2M |
| woodline partners lp | 1,476,064 | $20.5M |
Showing top 10 of 190 institutional holders of Janux Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Janux Therapeutics, Inc.'s pipeline?
Janux Therapeutics, Inc. (JANX) has 52 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Janux Therapeutics, Inc.'s lead drug candidate?
Janux Therapeutics, Inc.'s most advanced tracked candidate is [²¹²Pb]Pb-ADVC001 (Phase 1) for Prostate Cancer.
What is Janux Therapeutics, Inc.'s next catalyst?
Janux Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: FIRMAGON" — expected April 27, 2032.
What is Janux Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Janux Therapeutics, Inc. has approximately 224.9 months of cash runway.
What is Janux Therapeutics, Inc.'s market capitalization?
Janux Therapeutics, Inc.'s market capitalization is approximately $865.7M.
Get the full picture on Janux Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.